In the last market update, Goldman Sax raised the end of the year’s S&P 500 (SPX) expectations to 6900 by the end of the year, an increase from a previous roof of 6500, and the science of three shares should enjoy investors on their radar, including two index and the other is an opportunity to grow out of abundance.
And Joldman is not alone. Several major investment banks are calibrating their expectations for 2025 S&P 500 (SPX) in the middle of the year, reflecting the renewed optimistic about economic flexibility, stabilizing inflation, and a smooth decline.
Bank of America, for example, She also raised the goal of the S&P 500, raising its expectations at the end of the year from 5600 to 6300, although it hit a more cautious tone. Strategic expert Savita Subramanian noted that slowing technology profits and mixed macro data can limit more bullish trend in the short term.
Currently, SPX 6,263 is An increase of 6.49 % from year to date and 14.8 % in the past three months. Goldman expects to gradually expand over the next ninety days, with an increase of 3 % in S&P 500, followed by a 6 % profit in the last three months of the year.
At the core of Goldman’s Saudi thesis are strong basics and favorable policy dynamics. The Wall Street is growing for the S&P 500 profitability (EPS) to grow at a rate of 7 % both this year and in the next, and is fueled by the strong demand for consumers, the expansion of the margin, and the strong performance of the components of the higher indicator. An additional support from the federal reserve is expected to “previous and deeper” interest rates.
However, Goldman admits that the risks remain.
“The variable introductory scene creates a state of great uncertainty about our profit expectations, which are almost in line with consensus in 2025, but less than consensus in 2026,” David Coston, the main strategic expert of shares in the company, pointed out in the team’s report on July 7.
In light of all this, Goldman highlighted three shares to see them in the second half of 2025, which she believes is in a good position to take advantage of her thesis in the wider market. ColeNew York: KSSand Intellia TherapeuticsNasdaq: ntlaand and Gogo Inc.Nasdak: Jojo Are they associated with the structural trends that Goldman sees driving performance: retail, inventory of genes, and expansion of contact on board.
Kohl’s: Play a deep value with a transformation catalyst
Cole today
As of 07/15/2025
- 52 weeks
- 6.04 dollars
▼
23.02 dollars
- Profit
- 5.40 %
- P/E ratio.
- 8.50
- The target price
- 9.75 dollars
Kohl’s is trading 33.40 % for this year, although its share price is An increase of 20.5 % over the past 90 days. The stock also comes with a 5.35 % profit distribution.
Due to his short interest and a very reduced evaluation, Goldman sees Cool as a classic contradictory opportunity. Despite the ongoing challenges in the retail space, Kohl’s take strategic steps to re -put itself, such as focusing on stock discipline, cost reduction measures, and enhancing its loyalty program. This would help stabilize its revenues in the second half of the year.
In addition, Costin noted that the high floating debts shares should benefit from the decrease in bond yields when the Federal Reserve Discounts later carried out later in the year, as expected. Kohl must meet these standards, as it provides a rare part of the retail sector along with a decrease in multiple profit distributions and distributions estimated by income thinking investors.
Intellia Therapeutics: Liberation of genes with real momentum
Intellia Therapeutics today
Intellia Therapeutics
As of 04:00 pm
- 52 weeks
- $ 5.90
▼
$ 28.18
- The target price
- $ 33.37
The biotechnology company at Cambridge, Massachusetts has seen its headquarters The share price increased by 45.3 % last month-A great recovery of a company looking to find a solid foot in the genes editing space.
Intellia develops drugs with Krisper -based treatments, and the leading body treatments for rare genetic disorders, including genetic vascular edema and the disorder of the transformation (Attr). Although its programs remain in the clinical development in the early stage, Intellia obtained a great recognition of the strong intellectual property portfolio and scientific leadership, and has obtained credibility in both biotechnology societies and investors.
NTLA is a possible beneficiary of Eli Lilly’sNew York: Li Gain VERVE treatmentsNasdak: VerfSpecialized in hereditary cardiovascular drugs. The $ 1.3 billion deal filed the importance of genetic treatments and editing, as NTLA shines.
For investors who have tolerance with volatility, Intellia stands out as a long -term growth story that is currently being traded with a short -term discount, although recent stock prices are increased.
Gogo: Small Sleeping on the plane
Jojo today
As of 04:00 pm
- 52 weeks
- $ 6.17
▼
16.05 dollars
- The target price
- 12.63 dollars
Although it is not composed of the European National Congress Conference, the S&P 500, Gogo got a place on the Goldman radar thanks to its leadership in the commercial aviation connection. The company recently started covering Gogo with a purchase and targeted at $ 15, noting strong repeated revenues and offering the air network to the ground from the next generation of the next generation as major growth engines.
Gogo’s share price is A big increase of 117 % over the past three monthsAnd good times must last after getting a Gogo Certificate for an additional type of certificate for 42 types of aircraft through the US Federal Aviation Administration. The certificate includes 70 % of the current North American aircraft stocks.
In addition, Aerospace Technology has announced the first complete call ever using GOGO’s GOGO slides collection. This increases the 5G transmission outputs and expanded air communications transmission operations to land supported by a network of 170 grams 5G. GOGO “Go Full Go” expects a 5G chip by 2026.
While the bare chip development was led by Amnesty International and Hypersmiles, Gogo provides customers with an air infrastructure with the growth curve that has just began to decline with the start of 5G.
Gogo believes that Gogo is a good example of a specialized technology that should accelerate in the second half of 2025. In particular, Gogo shares meet Goldman’s growth format, which is a negative connection to the connection of the return, the frequent strong revenue model, and improve the background of capital markets, all of Gogo sites on a favorable path to the rest of 2025.
Before you think about Kohl, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has identified the five shares whom the top analysts quietly whispered to their customers to buy now before hunting the broader market … Kohl was not in the list.
While Kohl’s currently has a decrease in analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
With the spread of data and electric cars, the electrical network will get more tension. Download this report to find out how energy shares can play a role in your wallet with the continued growth of global energy demand.
